ライフサイエンスコーパス: RIT

1 RIT also promoted the apoptosis-like death of fungal cel

2 RIT can conceivably target such disease and improve canc

3 RIT clearance was not affected by treatment with HB22.7.

4 RIT of CN with (213)Bi- and (188)Re-labeled specific mAb

5 RIT of fungal cells using specific antibodies labeled wi

6 RIT significantly slowed down the growth of OS-17 and 14

7 RIT was associated with changes in concentration of the

8 RIT-mediated haploidentical BMT without TBI may increase

9 RIT-seq profiling identifies both known drug importers a

10 RITs have shown efficacy in refractory hairy cell leukem

11 (n = 24), Cilengitide-treated mice (n = 18), RIT (200-260 mu Ci (90)Y-labeled 1,4,7,10-tetraazacyclod

12 In syngeneic HSCT studies, (211)At-B10-30F11 RIT improved the median survival of leukemic mice in a d

13 of a conventional cylindrical ion trap and a RIT of 4 times greater volume show an improvement of 40

14 Furthermore, CD38 has not been explored as a RIT target despite its uniform high expression on malign

15 d BALB/c mice with multiple doses of SS1P, a RIT whose Ab portion targets mesothelin.

16 Soon after tracer dose and after RIT, mean SUV-lean of the other 6 responders decreased t

17 6-7 d after the tracer dose, and 5-7 d after RIT to estimate the early response to tracer dose and RI

18 At 33-70 d after RIT, mean SUV-lean of 6 responders markedly declined to

19 was performed at baseline and 33-70 d after RIT.

20 of tumor and endothelial cells 5 days after RIT compared with tumors from mice given RIT alone.

21 ped human antimurine antibodies (HAMA) after RIT.

22 tered simultaneously with and 24 hours after RIT, and in the RIT treatment groups, this translated in

23 ith HB22.7 simultaneously and 24 hours after RIT, respectively.

24 mained protein bound in blood 66 hours after RIT.

25 fore, simultaneously with, or 24 hours after RIT.

26 FDG PET metabolic data obtained 1-2 mo after RIT correlate well with the ultimate best response of NH

27 in vivo therapeutic efficacy was noted after RIT-INP-G3139 administration in a disseminated xenograft

28 standard whole-abdominal radiotherapy after RIT did not experience unexpected toxicity.

29 variable analyses of the LLQ scores and age, RIT, AMD severity, subfoveal choroidal thickness [SFCT],

30 lizing Abs to Pseudomonas exotoxin, allowing RIT treatment.

31 This study highlights alpha-RIT potency in MM treatment.

32 This study highlights the potency of alpha-RIT in MM treatment.

33 tudy, we investigated the potential of alpha-RIT with (212)Pb-Daratumumab (anti-CD38), in both in vit

34 tudy, we investigated the potential of alpha-RIT with (212)Pb-daratumumab (anti-hCD38), in both in vi

35 alpha-radioimmunotherapy (alpha-RIT) represents an attractive treatment strategy because

36 Alpha-radioimmunotherapy (alpha-RIT) represents an attractive treatment strategy due to

37 In all multivariable analyses, RIT had a stronger association than choroidal thickness.

38 conclusion, CMRIT, combining Cilengitide and RIT, significantly increased the efficacy of therapy and

39 timate the early response to tracer dose and RIT.

40 of 543 participants having both genotype and RIT determination; 408 showed normal macular health and

41 coring the success of both immunotherapy and RIT in the treatment of NHL.

42 n the antifungal activity of macrophages and RIT, suggesting the potential for synergistic action in

43 adult, neonate, and maternal yaws by PCR and RIT clearly demonstrated that, unlike syphilis, there wa

44 Both gamma-radiation and RIT caused cell death via an apoptotic-like pathway with

45 h to consider in radioimmunoscintigraphy and RIT.

46 ho had chemotherapy-sensitive disease before RIT had current PFS and OS rates at 4 years of 55% and 5

47 antation (BMT) with 300 muCi (90)Y-anti-CD45 RIT and CY, without TBI or fludarabine, led to mixed chi

48 ing and disease control supporting anti-CD45 RIT for T-NHL patients.

49 These data suggest that (211)At-anti-CD45 RIT in conjunction with HSCT may be a promising therapeu

50 uated the efficacy and toxicity of anti-CD45 RIT using (211)At in a disseminated murine AML model.

51 ble directly radiolabeled bivalent anti-CD45 RIT.

52 We evaluated anti-CD45-RIT in human (h) and murine (m) T-NHL.

53 ignificant improvement in PFS comparing CHOP-RIT with CHOP-R.

54 as 97% on the CHOP-R arm and 93% on the CHOP-RIT arm (P = .08).

55 as 76% on the CHOP-R arm and 80% on the CHOP-RIT arm (P = .11).

56 e cure rate for mice that received 260 mu Ci RIT increasing from 15 to 53% (P = 0.011).

57 This motif, together with classical RITs, account for up to 90% of all the significantly str

58 In this report, both conventional RIT (directly radiolabeled antibody) and streptavidin-bi

59 1 ratio reported previously for conventional RIT.

60 respectively) compared with the conventional RIT controls (2.6:1, 6.4:1, and 2.9:1, respectively).

61 livering RIT may be superior to conventional RIT when targeting CD45 for the treatment of leukemia an

62 that were markedly superior to conventional RIT.

63 ith tolerable toxicity, whereas conventional RIT with (90)Y-1F5 at a dose of 14.8 MBq (400 micro Ci)

64 compared with mice treated with conventional RIT using (90)Y-labeled anti-hCD45 Ab at 200 muCi.

65 fficacy of pretargeted RIT with conventional RIT using an anti-CD20 antibody.

66 c ratio than that achieved with conventional RIT using the same antibody.

67 ed anti-hCD45 RIT and <1:1 with conventional RIT.

68 nontarget tissues compared with conventional RIT.

69 ratios never exceeded 1:1 with conventional RIT.

70 boratory-scale mass spectrometer with a DAPI-RIT (rectilinear ion trap)-DAPI configuration has been d

71 gest that pretargeted methods for delivering RIT may be superior to conventional RIT when targeting C

72 pairs the clinical efficacy of CD20-directed RIT, imply that novel anti-CD20 MoAbs could also face th

73 Lower-dose RIT (200 mu Ci) combined with Cilengitide resulted in le

74 l compartmentalization of G3139-encapsulated RIT-INPs, resulting in reduced NF-kappaB activation, rob

75 e overall analytical capabilities of the ESI-RIT instrument were demonstrated with the analysis of a

76 firmed to have developed tMDS/tAML following RIT.

77 increase in cures (36 compared with 25% for RIT alone; P = 0.514).

78 has been the traditional target antigen for RIT of non-Hodgkin lymphoma (NHL), studies targeting HLA

79 with relapsed DLBCL should be considered for RIT versus autologous transplantation.

80 helator of (212)Bi, (213)Bi, and (177)Lu for RIT was evaluated in vitro and in vivo.

81 e of this approach in treatment planning for RIT.

82 To identify cells responsible for RIT removal, and the pathway by which RITs reach these c

83 s with extended follow-up suggest a role for RIT in chemotherapy-sensitive relapsed DLBCL, even in pa

84 CD45 may represent an alternative target for RIT in B-NHL.

85 e-labeled infusion of (131)I-tositumomab for RIT (January 1990 and April 2003) were reviewed.

86 atmospheric pressure ion (API) sources, four RIT mass analyzers, four sets of ion optical elements, a

87 Fractionated RIT using (90)Y-IT is an effective initial treatment for

88 Microvessel density in tumors from RIT and CMRIT mice was not different.

89 ter RIT compared with tumors from mice given RIT alone.

90 netics of alemtuzumab in 2 different groups: RIT (100 mg alemtuzumab in vivo over 5 days) and myeloab

91 hours were 20:1 using pretargeted anti-hCD45 RIT and <1:1 with conventional RIT.

92 HD-RIT may improve outcomes versus C-HDT in patients with r

93 d PFS were 67% and 48%, respectively, for HD-RIT and 53% and 29%, respectively, for C-HDT.

94 with either high-dose radioimmunotherapy (HD-RIT) using 131I-anti-CD20 (n = 27) or conventional high-

95 eatment-related mortality was 3.7% in the HD-RIT group and 11% in the C-HDT group.

96 was estimated to be.076 at 8 years in the HD-RIT group and.086 at 7 years in the C-HDT group.

97 Patients treated with HD-RIT experienced improved overall survival (OS) (unadjust

98 ilar, although more patients treated with HD-RIT had an elevated pretransplantation level of lactate

99 Patients treated with HD-RIT received individualized therapeutic doses of 131I-to

100 Hence, RIT agents licensed for adult tumors are generally not a

101 For the combined sample, higher RIT (slower RMDA) was observed for both the A69S variant

102 igh-risk ARMS2 and CFH alleles showed higher RIT, in both healthy and AMD groups (adjusted P = 0.0002

103 variant in ARMS2 was associated with higher RIT (adjusted P = 0.0011), whereas the Y402H variant in

104 H variant of CFH were associated with higher RIT (adjusted P = 0.0182 and P = 0.0222, respectively).

105 ibe our efforts to make new less-immunogenic RITs by identifying and removing T- and B-cell epitopes

106 Recombinant immunotoxin (RIT) therapy is limited in patients by neutralizing Ab r

107 Recombinant immunotoxins (RIT) have been highly successful in cancer therapy due,

108 Recombinant immunotoxins (RITs) are chimeric proteins composed of an Fv and a prot

109 Recombinant immunotoxins (RITs) are chimeric proteins designed to treat cancer.

110 Recombinant immunotoxins (RITs) are chimeric proteins that are being developed for

111 Recombinant immunotoxins (RITs) are hybrid proteins used to treat cancer.

112 Recombinant immunotoxins (RITs) are potent anticancer agents that have produced ma

113 ascular permeability in an effort to improve RIT of solid tumors.

114 Alemtuzumab concentrations in RIT patients were in excess of that required to kill inf

115 a higher percentage of apoptosis observed in RIT-treated cells.

116 ubscale outcomes, adjusted for age, included RIT, with total LLQ score, "driving," "extreme lighting,

117 Increased RIT was associated significantly with increasing AMD sev

118 eutic radioisotopes into tumors for internal RIT, or chemotherapeutic drugs for synergistically combi

119 IP RIT (131)I-omburtamab was well tolerated with minimal to

120 reach these cells, we studied SS1P, a 63-kDa RIT that targets mesothelin-expressing tumors and has a

121 correlated with prolonged DA testing (longer RIT) and decreased choroidal thickness.

122 pe of linear regression fits of longitudinal RIT data.

123 ials with radiolabeled anti-B-cell NHL mAbs, RIT promises to become integral to nuclear medicine prac

124 nted with CRT-D or an ICD, enrolled in MADIT-RIT.

125 sults for the ICD-only patients in the MADIT-RIT study (Multicenter Automatic Defibrillator Implantat

126 on Trial-Reduce Inappropriate Therapy (MADIT-RIT) randomized patients with a primary prophylactic ICD

127 on Trial-Reduce Inappropriate therapy (MADIT-RIT) trial showed a significant reduction in inappropria

128 on Trial-Reduce Inappropriate Therapy [MADIT-RIT], Avoid Delivering Therapies for Non-sustained Arrhy

129 e, the deimmunized toxin can be used to make RITs targeting other antigens, and the approach we descr

130 /116 [13%]) had a significantly greater mean RIT compared with eyes without RPD in any AMD severity g

131 In mice, RIT and LOP induced mild ER stress and inhibition of sar

132 peptide ChL6; n = 46), and combined modality RIT (CMRIT) using RIT and six doses of Cilengitide (250

133 This multiplexed RIT mass spectrometer employs an array of four millimete

134 we used this information to construct mutant RITs that are highly cytotoxic and do not stimulate T-ce

135 Myeloablative RIT and ASCT is a safe and effective therapeutic option

136 ximab)-conjugated lipopolyplex nanoparticle (RIT-INP)- and Bcl-2-targeted antisense G3139 as archetyp

137 Comparing amounts of RIT delivered in vivo and in vitro can explain tumor res

138 The combination of RIT with topotecan substantially reduced growth of relat

139 In this article, the basic concepts of RIT are reviewed with important milestones in its develo

140 ems make neutralizing Abs after one cycle of RIT, preventing repeated dosing.

141 nd sets the stage for further development of RIT of OS using comparative oncology.

142 ate neutralizing Ab levels, making dosing of RIT possible in mice already immune to RIT.

143 ethod that can increase the effectiveness of RIT, while decreasing the toxicities associated with dir

144 , suggesting that the therapeutic effects of RIT may result from changes in the inflammatory response

145 A) has been shown to augment the efficacy of RIT and decrease toxicity compared with a directly label

146 tumor site and thus improve the efficacy of RIT by combination with other treatment modalities.

147 s suggest that the antimicrobial efficacy of RIT involves killing through promotion of fungal cell ap

148 To compare the efficacy of RIT with that of amphotericin B, we infected AJ/Cr mice

149 toxicity, and become the next generation of RIT.

150 RIT were identified by live mouse imaging of RIT labeled with FNIR-Z-759.

151 demonstrate that DDR1 is a key modulator of RIT activity and represents a novel therapeutic strategy

152 o support trophozoite growth in the order of RIT > Cos7 > Caco2.

153 exploration of the therapeutic potential of RIT has been challenged by the absence of adequate ligan

154 uring follow-up demonstrated higher rates of RIT prolongation relative to those that did not (P < 0.0

155 % were female) revealed that higher rates of RIT prolongation were correlated with AMD severity group

156 Overall, higher rates of RIT prolongation were significantly correlated with grea

157 ne physicians with a better understanding of RIT capabilities and limitations in B-cell NHL and their

158 nvolvement, when needed, to allow the use of RIT and can suppress HAMA responses.

159 for the expected widespread clinical use of RIT in the management of B-cell NHL, alone or in combina

160 To enhance the therapeutic efficacy of RITs, we conducted a kinome RNAi sensitization screen, w

161 er analysis of species where a low number of RITs were predicted revealed a highly conserved structur

162 fore, we investigated the effects of DDR1 on RIT.

163 RG7787 is a clinically optimized RIT consisting of a humanized anti-mesothelin Fab fused

164 tly than the early data after tracer dose or RIT.

165 After irradiation or RIT, the cells were plated for colony-forming units (CFU

166 We therefore conducted pretargeted (P)RIT studies to augment the efficacy in mice of therapy u

167 NIE, a probabilistic approach for predicting RITs.

168 Pretargeted RIT (PRIT) using antibody-streptavidin (Ab-SA) construct

169 Pretargeted RIT using a covalent conjugate of the 1F5 anti-CD20 Ab w

170 Pretargeted RIT with 29.6 MBq (800 micro Ci) (90)Y-DOTA-biotin cured

171 and ABC-DLBCL xenografts with a pretargeted RIT (PRIT) system directed against the CD20 antigen.

172 progression-free survival after pretargeted RIT varied depending upon the lymphoma cell line used, w

173 ntibody) and streptavidin-biotin pretargeted RIT (PRIT) directed against the CD38 antigen were assess

174 e results suggest that anti-CD20 pretargeted RIT may be superior to conventional radiolabeled antibod

175 trates the marked superiority of pretargeted RIT for each of the antigenic targets with more complete

176 that clinical implementation of pretargeted RIT methods will provide a meaningful prolongation of su

177 ity, and therapeutic efficacy of pretargeted RIT with conventional RIT using an anti-CD20 antibody.

178 Nine patients received 3-step pretargeted RIT: (a) 160 mg/m2 of CC49 fusion protein, (b) synthetic

179 e is substantially reduced using pretargeted RIT.

180 no prior myeloablative therapy, and no prior RIT.

181 We have produced RITs that contain PE38, a portion of the bacterial prote

182 R-RIT showed a favorable benefit and risk profile in advan

183 openia or leukocytopenia was observed in 5 R-RIT patients, lasting 4-129 d.

184 h Hodgkin lymphoma (HL), were eligible for R-RIT (a priori criteria-based target-to-bone marrow ratio

185 ese results warrant further exploration of R-RIT in larger phase II clinical trials.

186 activity of radretumab radioimmunotherapy (R-RIT) were evaluated in 18 relapsed lymphoma or multiple

187 Both multiple myeloma patients receiving R-RIT experienced stabilization of disease.

188 Radioimmunotherapy (RIT) for pediatric tumors remains in its infancy despite

189 Radioimmunotherapy (RIT) for treatment of hematologic malignancies frequentl

190 Radioimmunotherapy (RIT) is a new treatment modality for B-cell non-Hodgkin'

191 Radioimmunotherapy (RIT) options for T-cell non-Hodgkin lymphomas (T-NHLs) a

192 Radioimmunotherapy (RIT) prolongs the survival of mice infected with Cryptoc

193 Radioimmunotherapy (RIT) using (131)I-tositumomab has been used successfully

194 Radioimmunotherapy (RIT) using monoclonal antibodies labeled with beta-emitt

195 Radioimmunotherapy (RIT) with alpha-emitting radionuclides is an attractive

196 Radioimmunotherapy (RIT) with yttrium-90 ((90)Y)-labeled anti-CD20 antibody

197 (90)Y-DOTA-peptide-Lym-1 radioimmunotherapy (RIT).

198 radioimmunodetection and radioimmunotherapy (RIT).

199 mmunodetection (RID) and radioimmunotherapy (RIT).

200 CID mice and followed by radioimmunotherapy (RIT) with 177Lutetium-2G11 and safety evaluation.

201 Myeloablative anti-CD20 radioimmunotherapy (RIT) can deliver curative radiation doses to tumor sites

202 imen employing anti-CD45 radioimmunotherapy (RIT) replacing total body irradiation (TBI) before haplo

203 Clinical radioimmunotherapy (RIT) of solid tumors holds great promise, but as yet has

204 mpared with conventional radioimmunotherapy (RIT) and at the same time preserve the efficiency of tum

205 control by CD20-directed radioimmunotherapy (RIT), but had no impact on targeting CD45.

206 al yttrium chelators for radioimmunotherapy (RIT) have been prepared via a convenient and high-yield

207 dosimetry and (90)Y for radioimmunotherapy (RIT).

208 roceeded to fractionated radioimmunotherapy (RIT) only if a repeat BM biopsy demonstrated clearing of

209 agnosis and 2 years from radioimmunotherapy (RIT) for previously treated patients, and 4.6 years from

210 odgkin's lymphoma (NHL), radioimmunotherapy (RIT) has finally come of age as a new therapeutic modali

211 The usefulness of radioimmunotherapy (RIT) for infectious diseases was recently demonstrated f

212 The efficacy of radioimmunotherapy (RIT) for patients with relapsed non-Hodgkin lymphoma (NH

213 ut the potential role of radioimmunotherapy (RIT) in the management of plasmacytomas and multiple mye

214 the clinical success of radioimmunotherapy (RIT).

215 nal beam radiotherapy or radioimmunotherapy (RIT), which joins the selectivity of antibody targeting

216 (Abs) and of pretargeted radioimmunotherapy (RIT) using Ab-streptavidin (SA) conjugates, followed by

217 Pretargeted radioimmunotherapy (RIT) using CC49 fusion protein, comprised of CC49-(scFv)

218 Pretargeted radioimmunotherapy (RIT) using streptavidin (sAv)-conjugated antibodies befo

219 cancer is responsive to radioimmunotherapy (RIT), a systemic targeted radiation modality, complete a

220 iodine I-131 tositumomab radioimmunotherapy (RIT).

221 novel strategy is to use radioimmunotherapy (RIT) with fungal-binding monoclonal antibodies (mAbs) la

222 llogeneic HCT data using radioimmunotherapy (RIT) and focuses on recent trials involving patients at

223 momab tiuxetan (Zevalin) radioimmunotherapy (RIT) was safe and effective for relapsed or refractory C

224 t antibody (conventional radioimmunotherapy [RIT]).

225 geted radiation therapy (radioimmunotherapy, RIT) employs a bifunctional ligand that can effectively

226 es with Caco2, Cos7, and mouse tumor rectal (RIT) cell lines using hybridoma-screened Dulbecco's modi

227 The major organs that remove RIT were identified by live mouse imaging of RIT labeled

228 In contrast to conventional RID/RIT where the radionuclides and oncotropic vector molecu

229 HHs) with alcohol and the HIV PIs ritonavir (RIT) and lopinavir (LOP).

230 me-scale RNA interference target sequencing (RIT-seq) screens in Trypanosoma brucei, revealing the tr

231 survival compared with conventional one-step RIT.

232 d on neovasculature, could increase systemic RIT efficacy of therapy in a human breast cancer tumor m

233 of topotecan and the specificity of systemic RIT to establish a novel therapy for solid tumors in an

234 Bacterial Rho-independent terminators (RITs) are important genomic landmarks involved in gene r

235 examined by PCR and rabbit infectivity test (RIT), were all negative.

236 local functional measurements of DA testing (RIT) and choroidal thickness are associated with patient

237 m at 40 d is more rapid after FIT (97%) than RIT (36.5%), irrespective of blood myeloid engraftment.

238 We conclude that RIT is more effective than amphotericin B against system

239 encountered, there is growing evidence that RIT can have a significant impact on the treatment of ca

240 Dosimetry calculations showed that RIT was approximately 1,000-fold more efficient in killi

241 The RIT mass spectrometer, which was assembled in two differ

242 The RIT prolongation as a measure of changing DA function ma

243 The RIT, defined as the time taken after a photobleach for v

244 ompared favorably with the untreated and the RIT alone groups, which had survival rates of 38% and 43

245 removing T- and B-cell epitopes to hide the RIT from the immune system.

246 (ii) The RIT can also be operated as a continuous rf/dc mass filt

247 ocyte counts were significantly lower in the RIT group persisting beyond 6 months after transplantati

248 ify and silence human B-cell epitopes in the RIT HA22.

249 sion of agonist peptides of human C5a in the RIT scheme results in improved tumor responses without a

250 usly with and 24 hours after RIT, and in the RIT treatment groups, this translated into the greatest

251 The mass resolution (50% definition) of the RIT in the trapping mode (radial ion ejection) is approx

252 The demonstrated capabilities of the RIT include tandem mass spectrometry, a mass resolution

253 duced dissociation (CID) capabilities of the RIT instrument were evaluated by measuring isolation eff

254 o Pseudomonas exotoxin, the component of the RIT that elicits the neutralizing Ab response.

255 A which consists of the toxin moiety of the RIT, and used this information to make LMB-T18 in which

256 from the higher ion trapping capacity of the RIT.

257 ce using continuous rf/dc filtering with the RIT.

258 he toxin to the cancer cell, but most of the RITs do not reach the tumor and are removed by other org

259 play library containing Fvs that bind to the RITs.

260 py (EBRT) and internal radioisotope therapy (RIT) has been widely used for clinical cancer treatment.

261 Optimism remains that these RIT approaches will improve the cure rates of allogeneic

262 The toxin portion of this RIT (LR-LO10) can be used with Fvs targeting other cance

263 daptation was defined by rod intercept time (RIT), duration (in minutes) required for sensitivity to

264 me of this study was the rod intercept time (RIT), which is defined as the time for a participant's v

265 rk adaptometer measuring rod intercept time (RIT).

266 linical trials of (90)Y-ibritumomab tiuxetan RIT for relapsed or refractory B-cell non-Hodgkin's lymp

267 Single-dose (90)Y ibritumomab tiuxetan RIT has an acceptable safety profile in relapsed NHL pat

268 eated safely with (90)Y-ibritumomab tiuxetan RIT on the basis of a fixed, weight-adjusted dosing sche

269 let count) toxicity when HB22.7 was added to RIT.

270 was also unchanged when HB22.7 was added to RIT.

271 ng of RIT possible in mice already immune to RIT.

272 It is hypothesized that improvements to RIT of adenocarcinoma can be realized by inclusion of va

273 not increase resistance of C. neoformans to RIT in vivo.

274 ll with the ultimate best response of NHL to RIT, more significantly than the early data after tracer

275 We assessed the tumor metabolic response to RIT using FDG PET.

276 ned B cells from patients with antibodies to RITs, isolated the corresponding variable fragments (Fvs

277 e rapidly than reduced intensity transplant (RIT) at day 0, although the nadir is similar in both at

278 ioning allogeneic stem cell transplantation (RIT) for non-Hodgkin lymphoma (NHL) in 88 patients (low-

279 utcome of reduced-intensity transplantation (RIT) in a cohort of 48 consecutive patients with relapse

280 oning allogeneic stem cell transplantations (RITs) could impair immune reconstitution and reduce dono

281 ctrometer based on the rectilinear ion trap (RIT) analyzer was designed and constructed for simultane

282 er based on a rectilinear geometry ion trap (RIT) has been built, and its performance has been charac

283 tal ion trap (DIT) and rectilinear ion trap (RIT) have been proven to be very useful technology in th

284 e instrument employs a rectilinear ion trap (RIT) mass analyzer and is battery-operated, hand-portabl

285 A rectilinear ion trap (RIT) mass analyzer was incorporated into a mass spectrom

286 g surface, and a novel rectilinear ion trap (RIT) mass analyzer.

287 mass spectrometer with rectilinear ion trap (RIT) mass analyzers was designed, constructed, and chara

288 first mass filter is a rectilinear ion trap (RIT) operated in a continuous mass-selective mode to tra

289 46), and combined modality RIT (CMRIT) using RIT and six doses of Cilengitide (250 microg/dose; n = 4

290 esults strongly support the concept of using RIT as an antimicrobial modality.

291 rial infections, but the mechanisms by which RIT is effective against microbes are uncertain.

292 they share several tumor antigens for which RIT agents are now available.

293 HL is currently the only indication in which RIT has been proven to be effective, clinical trials are

294 le for RIT removal, and the pathway by which RITs reach these cells, we studied SS1P, a 63-kDa RIT th

295 combining CHOP-R induction chemotherapy with RIT consolidation and/or extended rituximab maintenance

296 When compared with RIT alone, there was no significant additional hematolog

297 was decreased in CMRIT tumors compared with RIT tumors at 6 days (ANOVA, P < 0.05).

298 ciation was the LLQ subscale of driving with RIT (r =-0.97, P < 0.001).

299 in the groups treated with RIT alone or with RIT and HB22.7 (CMIT), the reduction in tumor volume was

300 w blood vessel growth and may synergize with RIT to increase efficacy.

301 Within the groups treated with RIT alone or with RIT and HB22.7 (CMIT), the reduction i

302 In PHHs, treatment with RIT and LOP or alcohol alone increased messenger RNA of